| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $56.31B | — | +33.1% |
| Cost of Revenue | $10.22B | — | +34.9% |
| R&D Expense | $17.70B | — | +45.7% |
| SG&A Expense | $2.61B | — | +14.6% |
| Operating Income | $22.87B | — | +30.3% |
| Pre-tax Income | $21.75B | — | +18.3% |
| Income Tax | -$5.02B | — | -388.9% |
| Net Income | $26.77B | — | +60.9% |
| EPS (Basic) | $10.57 | — | +60.4% |
| EPS (Diluted) | $10.44 | — | +62.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $23.43B | -34.7% | -18.5% |
| Short-term Investments | $57.75B | +26.3% | +39.2% |
| Accounts Receivable | $17.47B | -11.6% | +20.4% |
| Current Assets | $109.77B | +1.0% | +21.7% |
| Total Assets | $395.25B | +8.0% | +41.1% |
| Current Liabilities | $46.75B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $32.23B | — | +34.1% |
| Capital Expenditures | $19.00B | — | +46.8% |
| Investing Cash Flow | -$33.68B | — | -68.3% |
| Financing Cash Flow | -$6.55B | — | +66.4% |
| Free Cash Flow | $13.23B | — | +19.3% |
| +38.0% |
| Long-term Debt | $58.75B | +0.0% | +103.8% |
| Total Liabilities | $151.57B | +1.9% | +59.2% |
| Stockholders' Equity | $243.68B | +12.2% | +31.7% |